Bifogade filer
Prenumeration
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
“We are expanding our product capabilities as well as advancing solutions that are directly aligned with our professional market focus in oral health.” Marco Witteveen, CEO of Magnasense AB
July – October 2024*
• Total income amounted to SEK 0M (0,2M)
• Loss before tax amounted to SEK -14,0M (-18,3M)
• Cash and cash equivalents at the end of the quarter was SEK 1,8M (23,4M)
• Earnings per share** SEK -0,32 (-0,61)
• Equity ratio*** at 30 September 2024 was -37 (12) %.
Significant events during the period
• Melissa Grant, Associate Professor at the University of Birmingham’s School of Dentistry, joined Magnasense’s Scientific Advisory Board.
• Aegirbio AB changed its name to Magnasense AB, to better reflect core assets and focus.
• Directed issues of 13,196,289 shares to Atlas Special Opportunities, including 12,249,215 shares following conversions of SEK 5,0M of loan notes, and a further issue of 947,074 transaction fee shares.
• Calls for payments of SEK 5,0M from Atlas Special Opportunities under Tranche 3 of the loan facility.
• Vicki Johnson joined Magnasense AB as Interim CFO, succeeding Christel Dahlberg.
• Payment period for business-critical supplier invoices totalling USD 970,000 extended (SEK 9,8M), with an agreement to issue 9.5 million warrants subject to approval at an EGM.
• A feasibility study to explore potential technology development opportunities with Salignostics Ltd was initiated.
• Filed a patent application for an advanced detection system designed to improve sensitivity and accuracy of magnetic test strips using superparamagnetic nanoparticles.
• Magnasense AB arranged short term loans totalling SEK 3,0M from board members.
Significant events after the period
• Directed issue to Atlas Special Opportunities of 13,090,908 shares being conversion of debt SEK 1,5M, and SEK 1,5M allotment of transaction fee shares.
* Compared to the same period in 2023
** Earnings per share: Profit for the period divided by the weighted average number of shares, which as of 2024-09-30 amounted to 35,388,621 shares before dilution. The corresponding number for the same period in the previous year was 24,575,099 shares.
** Equity ratio: Equity divided by total capital.